This second episode in a 3-part series on HER3-targeted agents in NSCLC covers current clinical trials with HER3-targeted therapy, including:Recent data on patritumab deruxtecan (HER3-DXd) in the HERTHENA-Lung01 trialThe EGFRxHER3 bispecific antibodies BL-B01D1 and izalontamabThe HER2xHER3 bispecific antibody zenocutuzumabThe HER3-targeted antibody–drug conjugate SHR-A2009 Presenters in this series include:Rebecca S. Heist, MD, MPHAssociate Professor of MedicineHarvard Medical SchoolMedical OncologyMassachusetts General HospitalBoston, MassachusettsHelena Yu, MDAssociate AttendingDepartment of MedicineMemorial Sloan Kettering Cancer CenterNew York, New YorkSupported by an educational grant from Daiichi Sankyo, Inc. Link to full program, including a downloadable highlights slideset: https://bit.ly/48ecElW

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related